Tango Therapeutics is developing targeted cancer therapies using synthetic lethality to specifically target tumor cells based on their genetic profiles. This approach aims to enhance the efficacy of cancer treatments while minimizing harm to healthy tissues, addressing the limitations of traditional therapies.
Funding
$186M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BCFounders
Product
Problem
Traditional cancer therapies often harm healthy tissues alongside tumor cells, leading to significant side effects and limiting treatment efficacy. Targeting tumor cells specifically based on their genetic profiles remains a challenge.
Solution
Tango Therapeutics is developing targeted cancer therapies that leverage the principle of synthetic lethality to selectively target tumor cells based on their unique genetic vulnerabilities. By exploiting these vulnerabilities, Tango aims to create treatments that are more effective and less toxic than conventional approaches. Their approach focuses on identifying pairs of genes where the inactivation of either gene alone is survivable, but the simultaneous inactivation of both leads to cell death, allowing for precise targeting of cancer cells while sparing healthy tissue. This strategy expands the reach of genetically targeted therapies, offering a more personalized and effective approach to cancer treatment.
Target Audience
The primary target audience includes cancer patients with genetically defined tumors and the oncologists treating them.
Features
- Focus on synthetic lethality to target specific tumor vulnerabilities.
- Development of therapies designed to minimize harm to healthy tissues.
- Genetically targeted approach for personalized cancer treatment.